Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751018 | 0.96 | EGFR (0.53) | EGFRKDRRETRAF1BRAF | |
| SCHEMBL17934351 | 0.94 | EGFR (0.60) | EGFRKDRRAF1BRAF | |
| SCHEMBL30664568 | 0.85 | KDR (0.47) | EGFRKDR | |
| SCHEMBL21750867 | 0.85 | KDR (0.47) | EGFRKDR | |
| SCHEMBL21774022 | 0.85 | KDR (0.47) | EGFRKDR | |
| SCHEMBL17934334 | 0.84 | EGFR (0.59) | EGFRKDRRET | |
| SCHEMBL17934408 | 0.84 | EGFR (0.57) | EGFRKDRRAF1BRAF | |
| SCHEMBL21751043 | 0.84 | KDR (0.51) | EGFRKDR | |
| SCHEMBL21775453 | 0.83 | KDR (0.47) | EGFRKDR | |
| SCHEMBL17934367 | 0.82 | EGFR (0.63) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BRAF, RAF1, ARAF | EGFR 363/4885KDR 5/4885RET 10/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | EGFR 363/4885KDR 5/4885RET 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.